LONDON (Reuters) - A once-monthly injection for multiple sclerosis from Biogen and AbbVie has been recommended for approval by European regulators, paving the way for its launch in the coming months.
The European Medicines Agency said on Friday its experts had endorsed Zinbryta, or daclizumab, for the treatment of relapsing forms of multiple sclerosis (MS), adding a new option to a range of modern MS therapies.
The positive opinion will now be referred to the European Commission, which normally grants marketing authorizations for medicines recommended by the agency within a couple of months.
The self-administered, under-the-skin injection is also currently being reviewed by regulators in the United States, Switzerland, Canada and Australia.
Reporting by Ben Hirschler; Editing by Mark Potter
Our Standards: The Thomson Reuters Trust Principles.